| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TSHR |
| Uniprot No | P16473 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-413aa |
| 氨基酸序列 | GMGCSSPPCECHQEEDFRVTCKDIQRIPSLPPSTQTLKLIETHLRTIPSHAFSNLPNISRIYVSIDVTLQQLESHSFYNLSKVTHIEIRNTRNLTYIDPDALKELPLLKFLGIFNTGLKMFPDLTKVYSTDIFFILEITDNPYMTSIPVNAFQGLCNETLTLKLYNNGFTSVQGYAFNGTKLDAVYLNKNKYLTVIDKDAFGGVYSGPSLLDVSQTSVTALPSKGLEHLKELIARNTWTLKKLPLSLSFLHLTRADLSYPSHCCAFKNQKKIRGILESLMCNESSMQSLRQRKSVNALNSPLHQEYEENLGDSIVGYKEKSKFQDTHNNAHYYVFFEEQEDEIIGFGQELKNPQEETLQAFDSHYDYTICGDSEDMVCTPKSDEFNPCEDIMG |
| 预测分子量 | 48.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于TSHR(促甲状腺激素受体)重组蛋白的参考文献摘要(基于公开文献信息整理，部分内容为示例性简述)：
1. **《Structural insights into TSH receptor activation by autoantibodies》**
- 作者：Fanelli, F. et al.
- 摘要：通过重组人TSHR胞外域蛋白的晶体结构分析，揭示了Graves病中自身抗体与TSHR的结合机制，阐明其如何模拟促甲状腺激素(TSH)激活受体信号通路的分子基础。
2. **《Recombinant TSH receptor autoantibodies for improved detection of Graves' disease》**
- 作者：Sanders, J. et al.
- 摘要：研究构建了重组TSHR抗原，用于开发高灵敏度ELISA检测法，显著提高了Graves病患者血清中刺激性抗体的检出率，为临床诊断提供新工具。
3. **《Expression and purification of functional TSHR extracellular domain in mammalian cells》**
- 作者：Rapoport, B. et al.
- 摘要：报道了一种哺乳动物细胞表达系统高效制备可溶性TSHR重组蛋白的方法，验证其保留天然构象及与TSH/抗体的结合活性，为药物筛选奠定基础。
4. **《TSHR-specific monoclonal antibodies derived from recombinant immunization》**
- 作者：McLachlan, S.M. et al.
- 摘要：利用重组TSHR蛋白免疫小鼠获得单克隆抗体，揭示不同表位抗体对受体功能的调节差异，为甲状腺自身免疫疾病的机制研究提供新视角。
注：以上信息为示例性整理，实际文献需通过PubMed或学术数据库检索具体标题及作者确认。
**Background of TSHR Recombinant Protein**
The thyroid-stimulating hormone receptor (TSHR) is a G protein-coupled receptor (GPCR) predominantly expressed on the surface of thyroid follicular cells. It plays a central role in regulating thyroid function by binding thyroid-stimulating hormone (TSH), which triggers intracellular signaling cascades (e.g., cAMP-PKA pathway) to stimulate thyroid hormone synthesis and secretion. Dysregulation of TSHR activity is linked to autoimmune and endocrine disorders, such as Graves’ disease (autoantibody-mediated hyperthyroidism) and hypothyroidism.
TSHR’s structure includes a large extracellular domain (ECD) responsible for hormone binding and a transmembrane domain mediating signal transduction. Its complexity, with multiple glycosylation sites and disulfide bonds, poses challenges for native purification. Recombinant TSHR proteins, produced via genetic engineering in heterologous systems (e.g., mammalian HEK293 or insect cells), overcome these limitations. These systems enable precise control of post-translational modifications, ensuring proper folding and functionality.
Recombinant TSHR is widely used in biomedical research and drug development. It serves as a critical tool for studying receptor-ligand interactions, autoantibody mechanisms in Graves’ disease, and screening TSH analogs or inhibitors. Additionally, it aids in developing diagnostic assays to detect pathogenic TSHR autoantibodies. Recent advances in structural biology, including cryo-EM studies of TSHR complexes, have further highlighted its therapeutic targeting potential. By providing a reproducible and scalable source of functional receptor protein, recombinant TSHR accelerates both basic research and clinical applications in thyroid-related pathologies.
×
